Clay Siegall Achievements for Seattle genetics

Seattle Genetics is a global oncology company that mainly studies human antibodies as seen in its sculpture, a simplified model of a human antibody. The company manipulates and packages the antibodies into drugs since it was founded in 1998. The human antibody was discovered that it releases a toxic substance into a cancer cell and kills them from inside.

Despite the years of ups and down, Seattle Genetics has managed to boast a market value of about $ 10 billion and almost 900 employees. Currently, Seattle Genetics is ranked as the largest biotech in Washington. Seattle is passionate like other companies to grow from biotech to big pharma. Therefore, it invests in research and marketing and is planning to add 200 employees.

Adcetris, one of Seattleā€™s primary drugs, is used to treat cancer of lymph system that spreads to other body organs, commonly called Hodgkin lymphoma. With positive results being encountered, the drug’s sales will improve tremendously. Seattle Genetics led by Clay Siegall, partnered with Takeda Oncology to raise capital for researching Adcetris. The partnership benefits the company as it opened a new office in Switzerland to improve their international marketing.

In 2016, Seattle genetics made sales of about $ 418 million averaging to 46% increase from 2014 sales. Seattle Genetics is currently focused mainly on an antibody-drug conjugate (ADC), a type of drug that targets antigens. ADC drugs attach to the outer membrane of cancer cells in Hodgkin lymphoma and other illnesses and then release a toxin inside the cell that kills them.

Dr. Clay Siegall earned a degree in Zoology from the University of Maryland. He then graduated from George Washington University with a Ph.D. in Genetics. He then worked from 1991 to 1997 with the Bristol-Myers Squibb Pharmaceutical Research Institute. He also serves at Alder Biopharmaceuticals on the Board of Directors.

Clay Siegall is the president, chairman and Chief Executive Officer at Seattle Genetics. Siegall co- founded the company in 1998. Under his leadership, Seattle Genetics has experienced tremendous improvements in providing antibody-based cancer therapies. He is focused on helping cancer patients find happiness.